Bicara Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series C

Recent Raise

$165M

Bicara Therapeutics is a clinical-stage biotech company focused on developing BCA101, a novel bifunctional inhibitor targeting EGFR and TGF-β pathways for the treatment of various cancers.